c-MET (Y1230H)
Sign in to save this workspaceMET · Variant type: point · HGVS: p.Y1230H
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Cabozantinib | 89.9% | 10.1% | 92.73 |
| 2 | Gilteritinib | 89.0% | 11.0% | 88.97 |
| 3 | Tivozanib | 87.7% | 12.3% | 92.42 |
| 4 | Pacritinib | 75.3% | 24.7% | 88.64 |
| 5 | Defactinib | 73.6% | 26.4% | 92.68 |
| 6 | Crizotinib | 69.3% | 30.7% | 91.39 |
| 7 | Selpercatinib | 59.0% | 41.0% | 96.72 |
| 8 | Repotrectinib | 57.2% | 42.8% | 84.21 |
| 9 | Neratinib | 47.7% | 52.3% | 93.18 |
| 10 | Capmatinib | 43.0% | 57.0% | 99.75 |
| 11 | Lenvatinib | 37.0% | 63.0% | 97.74 |
| 12 | Canertinib | 34.7% | 65.3% | 96.49 |
| 13 | Sunitinib | 29.3% | 70.7% | 91.73 |
| 14 | Fedratinib | 27.9% | 72.1% | 96.21 |
| 15 | Tepotinib | 24.6% | 75.4% | 99.75 |
| 16 | Fostamatinib | 23.0% | 77.0% | 96.74 |
| 17 | Axitinib | 21.1% | 78.9% | 93.23 |
| 18 | Abemaciclib | 21.1% | 78.9% | 91.48 |
| 19 | Vemurafenib | 21.0% | 79.0% | 96.49 |
| 20 | Afatinib | 20.0% | 80.0% | 98.50 |
| 21 | Regorafenib | 19.7% | 80.3% | 95.99 |
| 22 | Brigatinib | 17.5% | 82.5% | 82.96 |
| 23 | Everolimus | 15.2% | 84.8% | 100.00 |
| 24 | Ponatinib | 15.0% | 85.0% | 78.23 |
| 25 | Entrectinib | 14.0% | 86.0% | 93.69 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Cabozantinib | 89.9% | — | — |
| Gilteritinib | 89.0% | — | — |
| Tivozanib | 87.7% | — | — |
| Pacritinib | 75.3% | — | — |
| Defactinib | 73.6% | — | — |
| Crizotinib | 69.3% | — | — |
| Selpercatinib | 59.0% | — | — |
| Repotrectinib | 57.2% | — | — |
| Neratinib | 47.7% | — | — |
| Capmatinib | 43.0% | — | — |
| Lenvatinib | 37.0% | — | — |
| Canertinib | 34.7% | — | — |
| Sunitinib | 29.3% | — | — |
| Fedratinib | 27.9% | — | — |
| Tepotinib | 24.6% | — | — |
| Fostamatinib | 23.0% | — | — |
| Axitinib | 21.1% | — | — |
| Abemaciclib | 21.1% | — | — |
| Vemurafenib | 21.0% | — | — |
| Afatinib | 20.0% | — | — |
| Regorafenib | 19.7% | — | — |
| Brigatinib | 17.5% | — | — |
| Everolimus | 15.2% | — | — |
| Ponatinib | 15.0% | — | — |
| Entrectinib | 14.0% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.5ms